Pharma & Biotech Events & Conferences
Refine Search
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Pharmaceutical
French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from two Phase III open-label extension studies. 18 November 2024
Pharmaceutical
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE study of its Livdelzi (seladelpar). 16 November 2024
Pharmaceutical
French drugmaker Ipsen announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease (AASLD) congress. 16 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
Shanghai-based BioCity Biopharma has announced promising late-stage results from the Phase II 2-SUCCEED clinical trial of SC0062. 7 November 2024
Biotechnology
Results from the ARC-10 Phase III study of Arcus Biosciences and Gilead Sciences’ domvanalimab and zimberelimab combination therapy indicate a significant reduction in mortality risk for patients with certain advanced lung cancers. 7 November 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased weight loss at higher doses. 4 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with mirikizumab sustained stable, long-term remission across two types of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease. 28 October 2024
Biotechnology
California’s Vera Therapeutics has released 96-week follow-up results from its ORIGIN Phase IIb trial of atacicept, targeting IgA nephropathy (IgAN). 28 October 2024
Biotechnology
Sino-American biotech firm BeiGene has announced encouraging results from a planned interim analysis of the Phase III RATIONALE 303 trial of its anti-PD-1 antibody tislelizumab compared to docetaxel as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 13 April 2021
Biotechnology
Results from the randomized, double-blind, placebo-controlled Phase III trial CHRONOS-3 show a significant improvement in progression-free survival (PFS) with the investigational combination of Aliqopa (copanlisib) and rituximab given intravenously in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) compared to the combination of rituximab and placebo. 12 April 2021
Pharmaceutical
New results from the STEP Phase IIIa clinical trial program demonstrated weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4mg versus placebo. 24 March 2021
Biotechnology
US oral peptides specialist Chiasma’s shares were up 13% at $3.89 pre-market today, after the company announced the presentation of new positive clinical data from its MPOWERED Phase III trial of Mycapssa (octreotide) at the Endocrine Society’s annual meeting, ENDO 2021, being held virtually March 20-23, 2021. 23 March 2021
Pharmaceutical
A novel treatment for the viral disease CMV viremia, TAK-620 (maribavir), has generated positive results in the Phase III SOLSTICE trial. 16 March 2021
Biotechnology
Over the weekend, US pharma major Eli Lilly (NYSE: LLY) released new data on its investigational intravenous drug donanemab, indicating that it could slow the cognitive decline of patients with Alzheimer's disease, thus creating hope in an area of medicine research that has so far produced mostly a string of failures. 15 March 2021
Biotechnology
Gilead Sciences has announced new, long-term data from open-label extensions of two Phase III studies of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide). 8 March 2021
Biotechnology
French biotech Ipsen has presented new analyses from the Phase III CheckMate -9ER trial of Cabometyx (cabozantinib) and Opdivo (nivolumab) in renal cell carcinoma (RCC). 9 February 2021
Biotechnology
Findings from the Phase III KEYNOTE-598 trial show that combining Keytruda (pembrolizumab) with another immunotherapy, Yervoy (ipilimumab), failed to improve outcomes in first-line non-small cell lung cancer (NSCLC). 2 February 2021
Pharmaceutical
PharmaMar (MC: PHM) today announced new data for Zepzelca (lurbinectedin) in combination with irinotecan have been presented at an oral session during the IASLC 2020 World Lung Cancer Conference, which has been held virtually from January 28th-31. 1 February 2021
Pharmaceutical
At the 2020 World Conference on Lung Cancer, AstraZeneca has presented results from an exploratory analysis of the ADAURA Phase III trial, showing an extension to disease-free survival (DFS). 29 January 2021
Biotechnology
US biotech Five Prime Therapeutics has updated Phase II FIGHT data in gastric cancer - including subgroup data, safety data, and immediate next steps – which were presented as an oral late-breaker at ASCO Gastrointestinal Cancers Virtual Annual Symposium (ASCO: GI) on Friday. 16 January 2021
Biotechnology
Sharing results at the TOXINS 2021 conference, organized by the International Neurotoxin Association, French drugmaker Ipsen has announced new Phase III analyses for Dysport (abobotulinumtoxinA). 15 January 2021
Pharmaceutical
Swiss pharma giant Novartis has presented detailed results on its investigational STAMP inhibitor asciminib’s comparison with Pfizer’s (NYSE: PFE) Bosulif (bosutinib) at the 62nd American Society of Hematology Annual Meeting & Exposition (ASH). 8 December 2020
Biotechnology
The Johnson & Johnson subsidiary Janssen has presented new data from the Phase III ANDROMEDA study, which evaluated Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a treatment for patients with light chain (AL) amyloidosis. 8 December 2020
Biotechnology
Dutch gene therapy company uniQure today announced the late-breaking presentation of initial data from its pivotal, Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec, an investigational adeno-associated virus five (AAV5)-based gene therapy for the treatment of patients with severe and moderately severe hemophilia B. 8 December 2020
Biotechnology
US biopharma TG Therapeutics has announced two data sets at the 62nd American Society of Hematology (ASH) Annual Meeting. 7 December 2020
Biotechnology
Gilead Sciences company Kite has announced results from the primary analysis of ZUMA-5, a Phase II study evaluating Yescarta (axicabtagene ciloleucel) in adults with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) after at least two prior lines of therapy. 7 December 2020
Biotechnology
Swiss pharma major Roche has presented a new analysis of three-year follow-up data from the pivotal HAVEN 1-4 studies. 7 December 2020
Biotechnology
Kite today announced follow-up results from the pivotal ZUMA-2 trial of Tecartus (brexucabtagene autoleucel, formerly KTE-X19) in adult patients with relapsed or refractory mantle cell lymphoma (MCL), at the 62nd ASH Annual Meeting and Exposition. 7 December 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze